Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AmNurite S is an oral fixed-dose combination product developed by Health N U Therapeutics, containing the tricyclic antidepressant amitriptyline hydrochloride and the active vitamin B12 analogue methylcobalamin in a sustained-release formulation. Amitriptyline functions by inhibiting the reuptake of serotonin and norepinephrine at the synaptic cleft, which enhances descending inhibitory pain pathways in the spinal cord. Methylcobalamin acts as a cofactor for methionine synthase, playing a critical role in the methylation process required for the maintenance and regeneration of the myelin sheath. This dual-action approach is designed to provide symptomatic relief from neuropathic pain while supporting the structural repair of damaged peripheral nerves. It is typically utilized in the management of conditions such as diabetic neuropathy and postherpetic neuralgia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amitriptyline + methylcobalamin.